📰 Overactive Bladder News
Page 167 - Overactive Bladder News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Overactive Bladder. Real-time updates on events, politics, business and more.
July 13, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
July 5, 2022
Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences
June 26, 2022
Quotable quotes heard by <em>MedPage Today</em>'s reporters
June 10, 2022
One of the latest studies carried out in Portugal concluded that the prevalence of urine leakage in women was 35.1%, and of these, 14.6% stated that urinary...
May 15, 2022
New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium
May 13, 2022
Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the
May 11, 2022
/PRNewswire/ -- Valencia Technologies Corporation ("Valencia" or the "Company"), a privately held company, today announced it has retained PRIA Healthcare to...
May 10, 2022
/PRNewswire/ -- Valencia Technologies Corporation ("Valencia" or the "Company"), a privately held company, today announced it has retained PRIA Healthcare to...
May 2, 2022
Various alternative therapies and treatments for fractures, which include synthetic bone grafts, amputation, and allografts, as well as non-invasive therapies, such as electrical bone growth stimulation and low-intensity ultrasound stimulations, have been introduced, which are responsible for driving the global bone growth stimulators market.
April 21, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.